A comprehensive study on levan nanoparticles formation: Kinetics and self-assembly modeling

Investigating the cryoprotective efficacy of fructans in mammalian cell systems via a structure-functional perspective

Fructans have long been known with their role in protecting organisms against various stress factors due to their ability to induce controlled dehydration and support membrane stability. Considering the vital importance of such features in cryo-technologies, this study aimed to explore the cryoprotective efficacy of fructans in mammalian cell systems where structurally different fructan polymers were examined on in vitro cell models derived from organs such as the liver, frequently used in transplantation, osteoblast, and cord cells, commonly employed in cell banking, as well as human seminal fluids that are of vital importance in assisted reproductive technology. To gain insights into the fructan/membrane interplay, structural differences were linked to rheological properties as well as to lipid membrane interactions where both fluorescein leakage from unilamellar liposomes and membrane integrity of osteoblast cells were monitored. High survival rates obtained with human endothelial, osteoblast and liver cells for up to two months clearly showed that fructans could be considered as effective non-permeating cryoprotectants, especially for extended periods of cryopreservation. In trials with human seminal fluid, short chained levan in combination with human serum albumin and glycerol proved very effective in preserving semen samples across multiple patients without any morphological abnormalities.

Insights into the heterogeneity of levan polymers synthesized by levansucrase Bs-SacB from Bacillus subtilis 168

Levan is an enzymatically synthesized fructose polymer with widely reported structural heterogeneity depending on the producing levansucrase, the reaction conditions employed for its synthesis and the characterization techniques. We studied here the specific properties of levan produced by recombinant levansucrase from B. subtilis 168 (Bs-SacB), often characterized as a bimodal distribution, that is, a mixture of low and high molecular weight levan. We found significant differences between both levans in terms of the already reported molecular weight, size and morphology using different analytical methods. The low molecular weight levan consists of a non-uniform polymer ranging from 50 to 230 kDa, synthesized through a non-processive mechanism that can spontaneously form spherical nanoparticles in the reaction medium. In contrast, high molecular weight levan is a uniform polymer, most probably synthesized through a processive mechanism, with an average molecular weight of 30,750 kDa and a poorly defined nano-structure. This is the first report exploring differences in morphology between low and high molecular weight levans. Our findings demonstrate that only the low molecular weight levan forms spherical nanoparticles in the reaction medium and that high molecular weight levan is mainly composed of a 33,000 kDa fraction with a microgel behavior.

Similarities and differences of nano-sized levan synthesized by Bacillus haynesii at low and high temperatures: Characterization and bioactivity

Levan is a biopolymer with many different uses. Temperature is an important parameter in biopolymer synthesis. Herein, levan production was carried out from Bacillus haynesii, a thermophilic microorganism, in the temperature range of 4 °C-95 °C. The highest levan production was measured as 10.9 g/L at 37 °C. The synthesized samples were characterized by FTIR and NMR analysis. The particle size of the levan samples varied between 153 and 824.4 nm at different temperatures. In levan samples produced at high temperatures, the water absorption capacity is higher in accordance with the particle size. Irregularities were observed in the surface pores at temperatures of 60 °C and above. The highest emulsion capacity of 83.4 % was measured in the sample synthesized at 4 °C. The antioxidant activity of all levan samples synthesized at different temperatures was measured as 84 % on average. All synthesized levan samples showed antibacterial effect on pathogenic bacteria. In addition, levan synthesized at 45 °C showed the highest antimicrobial effect on E. coli ATCC 35218 with an inhibition zone of 21.3 ± 1.82 mm. Antimicrobial activity against yeast sample C. albicans, was measured only in levan samples synthesized at 80 °C, 90 °C, 95 °C temperatures. Levan synthesized from Bacillus haynesii at low and high temperatures showed differences in characterization and bioactivity.

Characterization, production optimization, and fructanogenic traits of levan in a new Microbacterium isolate

Levan is a high-valued β-(2,6)-linked fructan with promising physicochemical and physiological properties and has diverse potential applications in the food, nutraceutical, pharmaceutical and cosmetic industry, but its commercial availability is still restricted to the relatively high costs of production. In this study, a strain identified as Microbacterium sp. XL1 was isolated from soil and highly produced exopolysaccharide (EPS). HPLC, FTIR and NMR spectroscopy revealed XL1-EPS is a levan-type fructan connected by β-(2, 6) linkages. SEM, DLS and TGA-DSC analysis showed that XL1-EPS processed high morphological versatility, narrow size distribution in its solutions and excellent thermal stability. The levan yield reached 83.67 ± 4.06 g/L with corresponding productivity of 3.49 ± 0.17 g/L/h and a conversion yield of 39.8 ± 1.9 % using sucrose (210 g/L) as substrates under the optimal cultivation conditions concluded by the response surface methodology (RSM). More strikingly, the XL1 strain also has multi-type fructanases to generate levanbiose, kestose, DFA IV and other L-FOSs. These results suggest Microbacterium sp. XL1 is a promising strain to produce levan and can provide various levan/inulin-degrading enzymes to create a great diversity of FOSs.

Microbial Polysaccharide-Based Nanoformulations for Nutraceutical Delivery

In recent times, nutrition and diet have become prominent health paradigms due to sedentary lifestyle disorders. Preventive health care strategies are becoming increasingly popular instead of treating and managing diseases. A nutraceutical is an innovative concept that offers additional health benefits beyond its fundamental nutritional value. These nutraceuticals have the potential to reduce the exorbitant use of synthetic drugs because the modern medicine approach of treating diseases with high-tech, expensive supplements, and long-term consequences aggravates consumers. However, most nutraceuticals are plant-derived, making them susceptible to degradation and prone to chemical instability, poor solubility, unpleasant taste, and bioactivity loss before absorption to the targeted site. To counteract this problem, the bioavailability of these labile compounds can be maximized by encapsulating them in protective nanocarriers. It is crucial that nanoencapsulation technologies convert bioactive compounds into forms that can be easily combined with functional foods and beverages without adversely affecting their organoleptic properties. In recent years, nanoformulations using food-grade materials, such as polysaccharides, proteins, lipids, etc., have received considerable attention. Among them, microbial polysaccharides are biocompatible, nontoxic, and nonimmunogenic, and most of them are US-FDA approved and can undergo tailored modifications. The nanoformulation of microbial polysaccharide is a relatively new frontier which has several advantages over existing systems. The present article, for the first time, comprehensively reviews microbial polysaccharides-based nanodelivery systems for nutraceuticals and discusses various techno-commercial aspects of these nanotechnological preparations. Moreover, this has also attempted to draw a future research perspective in this area.

Production and bioactivities of nanoparticulated and ultrasonic-degraded levan generated by Erwinia tasmaniensis levansucrase in human osteosarcoma cells

Levan is a bioactive polysaccharide that can be synthesized by various microorganisms. In this study, the physicochemical properties and bioactivity of levan synthesized by recombinant levansucrase from Erwinia tasmaniensis were investigated. The synthesis conditions, including the enzyme concentration, substrate concentration, and temperature, were optimized. The obtained levan generally appeared as a cloudy suspension. However, it could transform into a hydrogel at concentrations exceeding 10 % (w/v). Then, ultrasonication was utilized to reduce the molecular weight and increase the bioavailability of levan. Dynamic light scattering (DLS) and gel permeation chromatography (GPC) indicated that the size of levan was significantly decreased by ultrasonication, whereas Fourier transform infrared spectroscopy, ¹H-nuclear magnetic resonance, and X-ray powder diffraction revealed that the chemical structure of levan was not changed. Finally, the bioactivities of both levan forms were examined using human osteosarcoma (Saos-2) cells. The result clearly illustrated that sonicated levan had higher antiproliferative activity in Saos-2 cells than original levan. Sonicated levan also activated Toll-like receptor expression at the mRNA level. These findings suggested the important beneficial applications of sonicated levan for the development of cancer therapies.

Enhancement of antioxidant activity of levan through the formation of nanoparticle systems with metal ions

Levan, a natural polymer, is widely used in biomedical applications, such as antioxidants, anti-inflammatory, and anti-tumor. The present study aimed to enhance the antioxidant activity of levan by combining it with various metal ions in the nanoparticle (NP) system. Levansucrase encoding gene from Bacillus licheniformis BK1 has been inserted into an expression vector and the obtained recombinant was labeled as Lsbl-bk1 (accession number MF774877.1). That enzyme was used for in vitro levan synthesis in 12% (w/v) sucrose as a substrate and about 4.28 mg/mL of levan was obtained. Levan-based metal ion NPs were synthesized using the coprecipitation method. In the production of NPs, levan acts as a reducing and stabilizing agent. Four types of levan-based metal ion NPs were synthesized, namely, levan–Fe²⁺ NPs, levan–Cu⁺ NPs, levan–Co²⁺ NPs, and levan–Zn²⁺ NPs. The transmission electron microscopy (TEM) technique was applied to visualize the size and shape of the synthesized levan–metal NPs. All levan-based metal ion NPs have a particle size of less than 100 nm, and even levan–Cu⁺ and levan–Zn²⁺ have particle sizes less than 50 nm. Levan–Fe²⁺ NPs and levan–Cu⁺ NPs exhibited prominent antioxidant activity with an inhibition level of up to 88% and 95%, respectively. And the inhibition level of two metal ion NPs had about 33%–40% higher antioxidant activity compared with the inhibition level of levan only. The two levan–metal ion NPs, therefore, have future prospects to be developed as the new formulation for the antioxidant drugs.